Rein Therapeutics (RNTX) Enterprise Value (2016 - 2025)
Rein Therapeutics (RNTX) has disclosed Enterprise Value for 10 consecutive years, with -$3.2 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 75.01% to -$3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.2 million through Dec 2025, up 75.01% year-over-year, with the annual reading at -$3.2 million for FY2025, 75.01% up from the prior year.
- Enterprise Value for Q4 2025 was -$3.2 million at Rein Therapeutics, up from -$4.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$3.2 million in Q4 2025, with the low at -$63.4 million in Q1 2021.
- Average Enterprise Value over 5 years is -$17.3 million, with a median of -$12.1 million recorded in 2023.
- The sharpest move saw Enterprise Value crashed 490.85% in 2021, then surged 90.69% in 2022.
- Over 5 years, Enterprise Value stood at -$3.6 million in 2021, then tumbled by 43.97% to -$5.2 million in 2022, then plummeted by 232.69% to -$17.4 million in 2023, then rose by 25.91% to -$12.9 million in 2024, then soared by 75.01% to -$3.2 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$3.2 million, -$4.0 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.